Hendrik Peter  Scholl net worth and biography

Hendrik Scholl Biography and Net Worth

Chief Medical Officer of Belite Bio

Prof Hendrik Scholl, MD, has served as the Chief Medical Officer of Belite Bio since September 2024. He is a clinically active retinal expert with more than two decades of expertise in treating retinal diseases, including Stargardt disease and age-related macular degeneration. Dr. Scholl served as the founding and scientific co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Chair of the Department of Ophthalmology of the University Hospital Basel. He currently serves as President of the European Vision Institute (EVI), Chairman of EVICR.net and its Expert Committee on Retinal Dystrophies, and Founder and President of ARVO-SWISS. In academia, Dr. Scholl has held leadership roles at key institutions, notably as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School, where he also led the Retinal Degeneration Clinic and the Visual Neurophysiology Service. Dr. Scholl is the coordinating principal investigator of the largest natural history study of Stargardt disease (ProgStar Study). He holds an honorary doctorate from Semmelweis University in Budapest, Hungary, and is Adjunct Professor at the Medical University of Vienna, Austria. Dr. Scholl graduated from the Eberhard-Karls-University Tübingen, Germany, with a Doctor of Medicine and Master of Arts. He was awarded a research fellowship from the German Research Foundation (DFG) at Moorfields Eye Hospital and Institute of Ophthalmology, University College London (UCL), United Kingdom, and later a DFG Heisenberg Professorship for Macular Diseases at the Eye Clinic of the Rheinische Friedrich-Wilhelms-University Bonn, Germany.

What is Hendrik Peter Scholl's net worth?

The estimated net worth of Hendrik Peter Scholl is at least $3.45 million as of June 16th, 2026. Dr. Scholl owns 25,000 shares of Belite Bio stock worth more than $3,454,750 as of June 17th. This net worth evaluation does not reflect any other assets that Dr. Scholl may own. Learn More about Hendrik Peter Scholl's net worth.

How do I contact Hendrik Peter Scholl?

The corporate mailing address for Dr. Scholl and other Belite Bio executives is , , . Belite Bio can also be reached via phone at 858-246-6240 and via email at [email protected]. Learn More on Hendrik Peter Scholl's contact information.

Has Hendrik Peter Scholl been buying or selling shares of Belite Bio?

Within the last three months, Hendrik Peter Scholl has sold $1,405,700.00 in Belite Bio stock. Most recently, Hendrik Peter Scholl sold 10,000 shares of the business's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $140.57, for a transaction totalling $1,405,700.00. Following the completion of the sale, the insider now directly owns 25,000 shares of the company's stock, valued at $3,514,250. Learn More on Hendrik Peter Scholl's trading history.

Who are Belite Bio's active insiders?

Belite Bio's insider roster includes Wan-Shan Chen (Director), Hao-Yuan Chuang (CFO), Nathan Mata (Chief Scientific Officer), and Hendrik Scholl (Chief Medical Officer). Learn More on Belite Bio's active insiders.

Are insiders buying or selling shares of Belite Bio?

In the last year, insiders at the sold shares 14 times. They sold a total of 36,166 shares worth more than $5,954,050.86. The most recent insider tranaction occured on June, 16th when insider Hendrik Peter Scholl sold 10,000 shares worth more than $1,405,700.00. Insiders at Belite Bio own 13.3% of the company. Learn More about insider trades at Belite Bio.

Information on this page was last updated on 6/16/2026.

Hendrik Peter Scholl Insider Trading History at Belite Bio

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2026Sell10,000$140.57$1,405,700.0025,000View SEC Filing Icon  
See Full Table

Hendrik Peter Scholl Buying and Selling Activity at Belite Bio

This chart shows Hendrik Peter Scholl's buying and selling at Belite Bio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Belite Bio Company Overview

Belite Bio logo
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Read More

Today's Range

Now: $138.19
Low: $136.09
High: $146.00

50 Day Range

MA: $152.98
Low: $134.93
High: $181.17

2 Week Range

Now: $138.19
Low: $56.10
High: $200.00

Volume

300,256 shs

Average Volume

236,191 shs

Market Capitalization

$5.54 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A